AAP
VRDN icon

Arax Advisory Partners’s Viridian Therapeutics VRDN Stock Holding History

Arax Advisory Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37K Buy
+238
New +$3.83K ﹤0.01% 4634
2026
Q1 		– Sell
-361
Closed -$11.2K – 4360
2025
Q4 		$11.2K Buy
361
+246
+214% +$6.75K ﹤0.01% 2407
2025
Q3 		$2.48K Buy
+115
New +$2.07K ﹤0.01% 3064

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arax Advisory Partners's VRDN Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 238 shares worth $4.37K. The stake represents ﹤0.01% of the portfolio and ranks #4634 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in VRDN as recently as Q4 2025.

Arax Advisory Partners first reported a position in VRDN in Q3 2025 and has held it in 3 quarters since. The position peaked at $11.2K in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Arax Advisory Partners held 238 shares of Viridian Therapeutics worth $4.37K as of Q2 2026.
  • Viridian Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4634 holding.
  • Arax Advisory Partners first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Viridian Therapeutics position peaked at $11.2K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.